Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2022 | Low-dose tamoxifen for the treatment of high-risk breast cancer

Andrea De Censi • 6 Dec 2022
SABCS 2022
Breast Cancer Tamoxifen

Andrea De Censi, MD, PhD, National Hospital E.O. Ospedali Galliera – S.C. Oncologia Medica, Genoa, Italy, discusses low-dose tamoxifen for the treatment of choice for high-risk breast cancer, including ductal carcinoma in situ (DCIS). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andrea De Censi

1:32
10-year results of a Phase III trial of low-dose tamoxifen in non-invasive breast cancer
Andrea De Censi • 6 Dec 2022
0:48
What to look forward to at SABCS 2022
Andrea De Censi • 6 Dec 2022
1:13
TAM-01: low-dose tamoxifen in women with breast intraepithelial neoplasia
Andrea De Censi • 6 Dec 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals